Microbot Medical (NASDAQ:MBOT – Get Free Report) had its price objective lowered by investment analysts at B. Riley Financial from $4.00 to $3.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. B. Riley Financial‘s price target suggests a potential upside of 316.09% from the company’s current price.
MBOT has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Microbot Medical in a report on Wednesday, October 21st. Wall Street Zen lowered Microbot Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 24th. Weiss Ratings lowered Microbot Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Zacks Research cut Microbot Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Finally, Citigroup reiterated a “market outperform” rating on shares of Microbot Medical in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.83.
Check Out Our Latest Stock Report on MBOT
Microbot Medical Stock Down 0.1%
Shares of Microbot Medical stock traded down $0.00 during trading on Thursday, hitting $0.72. 254,434 shares of the company were exchanged, compared to its average volume of 1,335,497. Microbot Medical has a fifty-two week low of $0.52 and a fifty-two week high of $2.85. The stock has a market capitalization of $48.43 million, a price-to-earnings ratio of -2.77 and a beta of 1.07. The firm has a 50 day moving average price of $1.12 and a 200 day moving average price of $1.78.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last announced its earnings results on Friday, November 13th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.01 million. Analysts predict that Microbot Medical will post -0.30 earnings per share for the current year.
Hedge Funds Weigh In On Microbot Medical
Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its position in shares of Microbot Medical by 1,688.1% in the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 71,560 shares during the period. Cetera Investment Advisers increased its stake in Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 13,099 shares during the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new position in Microbot Medical in the first quarter valued at $28,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.
About Microbot Medical
Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.
See Also
- Five stocks we like better than Microbot Medical
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
